Flow cytometric analysis of benign and malignant tumors

良性和恶性肿瘤的流式细胞术分析

• 批准号: 10703097
• 负责人: Hao-Wei Wang
• 金额: $ 197.66万
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10703097
• 关键词: AIDS related cancer; Acquired Immunodeficiency Syndrome; B-Cell Lymphomas; Benign; Biological Assay; Biopsy; Blood; Body Fluids; Bone Marrow; CCR; Cell Surface Proteins; Characteristics; Clinical; Clinical Protocols; Communities; Detection; Detection of Minimal Residual Disease; Diagnosis; Diagnostic tests; Disease; Education; Eligibility Determination; Enrollment; Evaluation; Event; Fine needle aspiration biopsy; Flow Cytometry; Goals; HIV; Human Herpesvirus 8; Immunophenotyping; Institution; Laboratories; Lymphoproliferative Disorders; Malignant - descriptor; Malignant Neoplasms; Measurement; Medical; Monitor; Neoplasms; Patients; Play; Protocols documentation; Research; Residual state; Role; System; Techniques; Testing; Tissues; Tumor Antigens; United States National Institutes of Health; cancer cell; cell determination; improved; leukemia/lymphoma; medical specialties; neoplastic cell; primary effusion lymphoma; prognostication; response; targeted treatment; therapeutic evaluation; treatment response

The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI and NIH patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated as requisite for enrolment in clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories or other academic institutions. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice. The Flow Cytometry Unit also continues to support ongoing research in the CCR HIV and AIDS Malignancy Branch, including flow cytometric detection of HIV-related malignancy such as primary effusion lymphoma, HHV8-associated B-cell lymphoma or lymphoproliferative disorders.

流式细胞仪为NCI临床方案提供广泛的支持，为白血病和淋巴瘤患者提供NCI临床方案或正在进行测试以确定是否符合上述方案的诊断测试。流式细胞术单元为NCI和NIH患者的血液、骨髓、细针抽吸、组织活检和体液提供临床流式细胞术评估。由流式细胞仪进行的大多数流式细胞仪检测涉及最小残留疾病的检测（患者在NCI方案入组前在外部机构治疗后的状态）和特定肿瘤细胞特征的测量，这是临床方案入组所必需的。该单位的重大努力致力于提供商业实验室或其他学术机构不提供的许多独特的协议规定的分析。流式细胞术组还积极参与NIH工作人员和医学界在医疗实践中流式细胞术的适当效用的教育。流式细胞术部门还继续支持CCR HIV和艾滋病恶性肿瘤分支正在进行的研究，包括流式细胞术检测HIV相关恶性肿瘤，如原发性积液性淋巴瘤、hhv8相关b细胞淋巴瘤或淋巴细胞增生性疾病。